Clinical Trials Logo

Clinical Trial Summary

This is a single arm, open-label, single-center, phase 1/2 study, to determine the safety and efficacy of TriCAR-T-CD19, an autologous tri-functional anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in refractory/Relapsed Non-Hodgkin Lymphoma (NHL).


Clinical Trial Description

The tri-functional anti-CD19 chimeric antigen receptor contains an anti-CD19 scFv, a PD-L1 blocker, and a cytokine complex, enabling the TriCAR-T-CD19 to simultaneously targeting the CD19 positive NHL´╝îblocking the inhibitory PD-L1 signal and stimulating T/NK cell activation and expansion. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03497533
Study type Interventional
Source Timmune Biotech Inc.
Contact Ming Zhou
Phone +86 0731 83928147
Email zhouming_0321@163.com
Status Recruiting
Phase Phase 1/Phase 2
Start date August 3, 2018
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03720496 - Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCAR-T Cell Therapy Phase 1
Recruiting NCT02081937 - CART-19 Immunotherapy in Mantle Cell Lymphoma Phase 1/Phase 2
Recruiting NCT03488251 - PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_002) Phase 2